<i>In vitro</i> and <i>in vivo</i> characterization of Bisphosphocin Nu-3—a novel broad-spectrum antimicrobial compound with high potency against resistant pathogens
Bibliographic record
Abstract
ABSTRACT Lakewood-Amedex Biotherapeutics Inc. has developed a new class of antimicrobials called the Bisphosphocin class, with Nu-3 as a leading candidate, which is currently in clinical development for treating mildly infected diabetic foot ulcers (iDFUs). Nu-3 acts through a novel mechanism of action that destabilizes bacterial membranes within minutes, which significantly reduces the potential for resistance development. It demonstrates broad-spectrum activity against Gram-positive, Gram-negative, and multidrug-resistant bacteria, including recent clinical isolates from infected wounds. Nu-3 is especially effective in acidic environments and can be formulated for topical application at high concentrations and low pH, that has been shown to be beneficial for wound healing, making it well-suited for treating infections in diabetic foot ulcers. Its rapid, bactericidal action has been confirmed against pathogens, such as Staphylococcus aureus , Escherichia coli , Pseudomonas aeruginosa, Klebsiella pneumoniae, Propionibacterium acnes, Proteus mirabilis, Acinetobacter baumannii, and Staphylococcus saprophyticus , with complete bacterial eradication occurring within minutes. Resistance testing over 21 days showed a very low probability of resistance development. In vivo testing in murine dermal methicillin-resistant Staphylococcus aureus (MRSA) infection models demonstrated robust efficacy for Nu-3 given as a solution- or gel-formulation in both single and multidose protocols. Given its efficacy, broad-spectrum activity, and topical formulation, Nu-3 has the potential to be an important therapeutic intervention for the treatment of mild infections in diabetic foot ulcers—a serious complication of diabetes associated with high amputation risk.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".